Compounds > n(6)-2-(4-amino-3-iodophenyl)ethyladenosine
Page last updated: 2024-09-03

n(6)-2-(4-amino-3-iodophenyl)ethyladenosine and cholecystokinin

n(6)-2-(4-amino-3-iodophenyl)ethyladenosine has been researched along with cholecystokinin in 1 studies

Compound Research Comparison

Studies
(n(6)-2-(4-amino-3-iodophenyl)ethyladenosine)		Trials
(n(6)-2-(4-amino-3-iodophenyl)ethyladenosine)		Recent Studies (post-2010)
(n(6)-2-(4-amino-3-iodophenyl)ethyladenosine)		Studies
(cholecystokinin)		Trials
(cholecystokinin)		Recent Studies (post-2010) (cholecystokinin)
60010,9144661,074

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bourgoin, S; Cesselin, F; Hamon, M; Mauborgne, A; Poliénor, H1

Other Studies

1 other study(ies) available for n(6)-2-(4-amino-3-iodophenyl)ethyladenosine and cholecystokinin

ArticleYear
Adenosine receptor-mediated control of in vitro release of pain-related neuropeptides from the rat spinal cord.
    European journal of pharmacology, 2002, Apr-19, Volume: 441, Issue:1-2

    Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Calcitonin Gene-Related Peptide; Cholecystokinin; Dose-Response Relationship, Drug; In Vitro Techniques; Male; Neuropeptides; Pain; Phenethylamines; Potassium; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; Spinal Cord; Substance P; Xanthines

2002